{"hands_on_practices": [{"introduction": "While serological tests are excellent screening tools, the definitive diagnosis of celiac disease often relies on the \"gold standard\" of a duodenal biopsy. This practice will challenge you to act as a pathologist, interpreting key histological features to grade the severity of mucosal damage using the Marsh classification. Mastering this fundamental skill is essential for confirming and staging celiac disease [@problem_id:4337267].", "problem": "A $28$-year-old patient with chronic iron deficiency anemia and bloating is found to have elevated Immunoglobulin A (IgA) anti-tissue transglutaminase antibodies and positive IgA anti-endomysial antibodies on serologic testing. A duodenal biopsy shows the following findings: increased intraepithelial lymphocytes (IELs) quantified at $35$ IELs per $100$ enterocytes, crypt elongation consistent with hyperplasia, and villous blunting such that the measured villus:crypt ratio is $1:1$. There is preservation of some villous structures without complete flattening.\n\nUsing the following fundamental base in small intestinal mucosal pathology: normal proximal small intestinal architecture has finger-like villi and shorter crypts with a villus:crypt ratio of approximately $3:1$ to $5:1$; immune-mediated injury to gluten-sensitive individuals produces increased IELs, crypt hyperplasia, and variably severe villous atrophy; and the Marsh classification stratifies lesions by presence of increased IELs, crypt hyperplasia, and the degree of villous atrophy, select the Marsh grade that best matches the histologic findings described.\n\nA. Marsh $1$ (infiltrative lesion with increased IELs and normal architecture)\n\nB. Marsh $2$ (hyperplastic lesion with increased IELs and crypt hyperplasia but no villous atrophy)\n\nC. Marsh $3\\text{a}$ (partial villous atrophy with increased IELs and crypt hyperplasia)\n\nD. Marsh $3\\text{c}$ (total villous atrophy with increased IELs and crypt hyperplasia)", "solution": "The problem statement will first be validated for scientific soundness, consistency, and well-posedness.\n\n### Step 1: Extract Givens\n-   Patient: $28$-year-old\n-   Clinical findings: Chronic iron deficiency anemia, bloating\n-   Serology: Elevated Immunoglobulin A (IgA) anti-tissue transglutaminase antibodies, positive IgA anti-endomysial antibodies\n-   Biopsy source: Duodenum\n-   Histologic finding 1: Increased intraepithelial lymphocytes (IELs), quantified at $35$ IELs per $100$ enterocytes.\n-   Histologic finding 2: Crypt elongation consistent with hyperplasia.\n-   Histologic finding 3: Villous blunting.\n-   Histologic finding 4: Measured villus:crypt ratio is $1:1$.\n-   Histologic finding 5: Preservation of some villous structures without complete flattening.\n-   Fundamental base 1: Normal proximal small intestine has a villus:crypt ratio of approximately $3:1$ to $5:1$.\n-   Fundamental base 2: Immune-mediated injury in celiac disease produces increased IELs, crypt hyperplasia, and villous atrophy.\n-   Fundamental base 3: The Marsh classification stratifies these lesions.\n-   Question: Select the Marsh grade that best matches the described histologic findings.\n\n### Step 2: Validate Using Extracted Givens\n1.  **Scientifically Grounded:** The problem describes a classic case of celiac disease. The clinical presentation (anemia, bloating), serological markers (anti-tTG IgA, anti-EMA IgA), and histopathological findings (increased IELs, crypt hyperplasia, villous atrophy) are all well-established and textbook features of this autoimmune disorder. The Marsh classification is the standard, internationally recognized system for grading the histopathology of celiac disease. The problem is firmly grounded in established medical science and pathology.\n2.  **Well-Posed:** The problem provides a clear set of observational data (histologic findings) and asks for their classification using a specified, defined system (Marsh classification). The information is sufficient and specific enough to map directly to one of the stages in the classification system, leading to a unique solution.\n3.  **Objective:** The language is precise and quantitative (e.g., \"$35$ IELs per $100$ enterocytes\", \"villus:crypt ratio is $1:1$\"). It avoids ambiguity and subjective claims.\n\nThe problem is free of scientific unsoundness, incompleteness, contradiction, or ambiguity. It represents a standard, formalizable task in medical diagnostics.\n\n### Step 3: Verdict and Action\nThe problem statement is **valid**. A solution will be derived.\n\n### Derivation\nThe Marsh classification (often referred to as the Marsh-Oberhuber classification) provides a stepwise grading of the severity of mucosal injury in celiac disease. The progression is based on three key histologic features: an increase in intraepithelial lymphocytes (IELs), the development of crypt hyperplasia, and the subsequent onset and worsening of villous atrophy.\n\nThe stages are defined as follows:\n-   **Marsh $0$**: Normal mucosa.\n-   **Marsh $1$ (Infiltrative lesion)**: Characterized by an increased number of IELs (typically defined as $>20-25$ IELs per $100$ enterocytes), but the villous architecture and crypts remain normal.\n-   **Marsh $2$ (Hyperplastic lesion)**: In addition to increased IELs, there is proliferation of crypt enterocytes, leading to crypt hyperplasia (elongation and increased mitotic activity). The villous architecture is still preserved (i.e., no villous atrophy).\n-   **Marsh $3$ (Destructive lesion)**: This stage represents the classic celiac lesion, characterized by the triad of increased IELs, crypt hyperplasia, and villous atrophy. It is subdivided based on the severity of the villous atrophy:\n    -   **Marsh $3\\text{a}$ (Partial villous atrophy)**: Villi are still present but are blunted and shortened. The villus:crypt (V:C) ratio is reduced, typically falling below the normal $3:1$ to near $1:1$.\n    -   **Marsh $3\\text{b}$ (Subtotal villous atrophy)**: Villi are markedly atrophic and difficult to discern.\n    -   **Marsh $3\\text{c}$ (Total villous atrophy)**: Villi are completely absent, resulting in a flat mucosal surface.\n-   **Marsh $4$ (Hypoplastic lesion)**: Total villous atrophy is present, but it is accompanied by crypt hypoplasia, not hyperplasia. This is a rare and severe form, often associated with refractory celiac disease.\n\nWe will now map the patient's findings to this classification system.\n1.  **Increased IELs**: The finding of $35$ IELs per $100$ enterocytes is significantly above the normal threshold, satisfying the criterion for Marsh $1$ and all subsequent stages.\n2.  **Crypt Hyperplasia**: The finding of \"crypt elongation consistent with hyperplasia\" satisfies the criterion for Marsh $2$ and all subsequent stages. This rules out Marsh $1$.\n3.  **Villous Atrophy**: The finding of \"villous blunting\" and a V:C ratio of $1:1$ indicates the presence of villous atrophy. This rules out Marsh $2$, which requires preserved villous architecture. The lesion must therefore be at least Marsh stage $3$.\n4.  **Degree of Atrophy**: The problem specifies \"preservation of some villous structures without complete flattening\". This finding distinguishes partial/subtotal atrophy from total atrophy. A V:C ratio of $1:1$ with persisting, albeit blunted, villi is the hallmark of partial villous atrophy. Total villous atrophy (Marsh $3\\text{c}$) would be described as a \"flat\" mucosa, which is explicitly contradicted by the given information.\n\nTherefore, the combination of increased IELs, crypt hyperplasia, and partial villous atrophy (blunting with a V:C ratio of $1:1$) corresponds precisely to the definition of a Marsh $3\\text{a}$ lesion.\n\n### Option-by-Option Analysis\n-   **A. Marsh $1$ (infiltrative lesion with increased IELs and normal architecture)**: Incorrect. The patient's biopsy shows crypt hyperplasia and villous atrophy (V:C ratio of $1:1$), which are abnormalities of the mucosal architecture. Marsh $1$ requires normal architecture apart from the IEL infiltration.\n-   **B. Marsh $2$ (hyperplastic lesion with increased IELs and crypt hyperplasia but no villous atrophy)**: Incorrect. The patient's biopsy clearly demonstrates villous atrophy, as evidenced by \"villous blunting\" and a V:C ratio of $1:1$. Marsh $2$ is defined by the absence of villous atrophy.\n-   **C. Marsh $3\\text{a}$ (partial villous atrophy with increased IELs and crypt hyperplasia)**: Correct. This option perfectly matches the constellation of findings: increased IELs ($35$/$100$), crypt hyperplasia, and partial villous atrophy (blunting with a V:C ratio of $1:1$).\n-   **D. Marsh $3\\text{c}$ (total villous atrophy with increased IELs and crypt hyperplasia)**: Incorrect. The problem statement explicitly notes \"preservation of some villous structures without complete flattening\". This is inconsistent with total villous atrophy, which describes a complete loss of villi and a flat mucosal surface.", "answer": "$$\\boxed{C}$$", "id": "4337267"}, {"introduction": "What happens when a patient has all the signs of celiac disease, but their blood tests are negative? This scenario explores the important concept of seronegative celiac disease, forcing a return to the first principles of immunopathogenesis—genetic susceptibility and gluten-dependent intestinal injury. This exercise demonstrates why the biopsy, especially following a controlled gluten challenge, can be the ultimate arbiter when serology is inconclusive [@problem_id:4337174].", "problem": "An adult patient has adhered to a strict gluten-free diet for approximately $12$ months due to chronic gastrointestinal symptoms. On this diet, tissue transglutaminase immunoglobulin A (tTG-IgA) serology is negative. Human leukocyte antigen DQ2 (HLA-DQ2) genotyping is positive. As part of a standardized gluten challenge, the patient consumes approximately $8$ grams of gluten per day for $6$ weeks and develops recurrent diarrhea. Esophagogastroduodenoscopy with duodenal biopsies reveals Marsh classification stage $3$ lesions (villous atrophy, crypt hyperplasia, and increased intraepithelial lymphocytes). Repeat tTG-IgA remains negative at the time of biopsy.\n\nUsing first principles of mucosal immunology, genetic predisposition, and the pathologic classification of celiac disease, which option best justifies why these findings support a diagnosis of celiac disease despite seronegativity?\n\nA. The combination of HLA-DQ2 positivity and the induction of Marsh $3$ lesions after gluten reintroduction demonstrates major histocompatibility complex class II–restricted antigen presentation of deamidated gliadin, activation of CD$4^{+}$ T cells, and cytokine-mediated mucosal injury characteristic of celiac disease; serologic markers may be absent if exposure is limited in duration or in selective immunoglobulin A deficiency, making biopsy after challenge a valid confirmatory approach.\n\nB. Negative tTG-IgA definitively excludes celiac disease because the assay is $100\\%$ sensitive and remains positive regardless of dietary gluten exposure, so histology cannot outweigh serology.\n\nC. HLA-DQ2 positivity alone is diagnostic of celiac disease; therefore, any biopsy findings are incidental and not required for diagnosis.\n\nD. Marsh $3$ lesions are nonspecific and can be entirely explained by lactose intolerance after gluten challenge, so celiac disease is unlikely.\n\nE. Only endomysial antibody (EMA) seroconversion can diagnose celiac disease; without EMA positivity, the diagnosis cannot be made even in the presence of Marsh $3$ changes following gluten challenge.", "solution": "The problem statement is evaluated as valid. It describes a coherent and clinically realistic scenario for the diagnosis of celiac disease, specifically the case of seronegative celiac disease. All provided information—patient history, dietary intervention, serological results, genetic testing, gluten challenge protocol, and histopathological findings—is consistent with established medical and scientific principles. The problem is well-posed, objective, and scientifically grounded, allowing for a rigorous analysis based on first principles of immunology and pathology.\n\n### Derivation from First Principles\n\nThe diagnosis of celiac disease rests on demonstrating a gluten-dependent enteropathy in a genetically susceptible individual. The core pathophysiology involves an adaptive immune response directed against gluten peptides in the small intestine.\n\n1.  **Genetic Susceptibility**: The vast majority ($>95\\%$) of individuals with celiac disease possess specific Human Leukocyte Antigen (HLA) class II haplotypes, either HLA-DQ2 or HLA-DQ8. These molecules are expressed on the surface of antigen-presenting cells (APCs), such as dendritic cells and macrophages, in the intestinal lamina propria. The patient's positive HLA-DQ2 genotype establishes this fundamental genetic predisposition.\n\n2.  **Antigen Processing and Presentation**: When a susceptible individual ingests gluten, its gliadin component peptides pass into the lamina propria. Here, the enzyme tissue transglutaminase $2$ (tTG2) deamidates specific glutamine residues within the gliadin peptides, converting them to glutamic acid. This modification significantly enhances the binding affinity of these peptides to the antigen-binding groove of the HLA-DQ2 or HLA-DQ8 molecules on APCs. The APCs then present these deamidated gliadin-peptide/HLA-DQ2 complexes on their surface.\n\n3.  **T-Cell Mediated Immunity and Mucosal Damage**: The presentation of these complexes to gluten-specific CD$4^{+}$ T helper cells in the lamina propria triggers their activation and proliferation. This is an MHC class II-restricted interaction. Activated CD$4^{+}$ T cells orchestrate an inflammatory cascade by releasing pro-inflammatory cytokines, most notably interferon-gamma (IFN-γ). This cytokine milieu leads to the characteristic histopathological changes of celiac disease:\n    *   **Villous atrophy**: Blunting and flattening of the intestinal villi, reducing the surface area for nutrient absorption.\n    *   **Crypt hyperplasia**: Elongation of the crypts of Lieberkühn as the intestinal stem cells attempt to regenerate the damaged epithelium.\n    *   **Increased intraepithelial lymphocytes (IELs)**: An influx of lymphocytes, primarily CD$8^{+}$ cytotoxic T cells, into the epithelial layer, which contributes directly to the destruction of enterocytes.\n    The patient's duodenal biopsy showing Marsh classification stage $3$ lesions (villous atrophy, crypt hyperplasia, and increased IELs) is the direct histological manifestation of this T-cell mediated process, induced by the reintroduction of gluten.\n\n4.  **Humoral (Antibody) Response**: The inflammatory process also activates B cells, leading to the production of antibodies. Key antibodies include those against deamidated gliadin peptides (anti-DGP) and against the tTG2 enzyme itself. Antibodies directed against tTG2 are detected by the tTG-IgA and the endomysial antibody (EMA) assays. Antibody production is gluten-dependent; levels typically fall and become undetectable after $6$-$12$ months on a strict gluten-free diet, explaining the patient's negative tTG-IgA result after $12$ months of adherence.\n\n5.  **Seronegativity in Active Disease**: The patient's tTG-IgA remains negative even after the $6$-week gluten challenge and confirmation of active disease via biopsy. This phenomenon, known as seronegative celiac disease, can occur for several reasons:\n    *   **Selective IgA Deficiency**: This is the most common reason. Approximately $2-3\\%$ of celiac patients have a systemic deficiency in producing Immunoglobulin A (IgA). In these cases, tTG-IgA and EMA-IgA tests will be falsely negative. Testing for tTG-IgG or total serum IgA is required to identify this condition.\n    *   **Insufficient Challenge Duration**: While a $6$-week challenge is standard, the serological response (rise in antibody titers) can lag behind the histological damage in some individuals. It may take longer than $6$ weeks for tTG-IgA to become positive.\n    *   **\"True\" Seronegativity**: A small subset of patients with biopsy-proven celiac disease do not mount a detectable antibody response to tTG, even without IgA deficiency.\n\nThe combination of HLA-DQ2 positivity (genetic predisposition), symptomatic relapse, and the development of classic Marsh $3$ histology upon a controlled gluten challenge provides definitive evidence for celiac disease, fulfilling all diagnostic criteria despite the negative serology.\n\n### Evaluation of Options\n\n**A. The combination of HLA-DQ2 positivity and the induction of Marsh $3$ lesions after gluten reintroduction demonstrates major histocompatibility complex class II–restricted antigen presentation of deamidated gliadin, activation of CD$4^{+}$ T cells, and cytokine-mediated mucosal injury characteristic of celiac disease; serologic markers may be absent if exposure is limited in duration or in selective immunoglobulin A deficiency, making biopsy after challenge a valid confirmatory approach.**\nThis option accurately describes the entire pathophysiological sequence from genetic predisposition (HLA-DQ2) to the cellular mechanism (MHC class II-restricted presentation, CD$4^{+}$ T cell activation) leading to the observed outcome (cytokine-mediated mucosal injury manifested as Marsh $3$ lesions). It also provides scientifically correct and clinically relevant explanations for the seronegativity (insufficient duration of challenge or IgA deficiency). It correctly states that biopsy after a challenge is a valid and, in this case, necessary confirmatory step.\n**Verdict: Correct**\n\n**B. Negative tTG-IgA definitively excludes celiac disease because the assay is $100\\%$ sensitive and remains positive regardless of dietary gluten exposure, so histology cannot outweigh serology.**\nThis statement is factually incorrect on multiple counts. The tTG-IgA test is not $100\\%$ sensitive. Its sensitivity is high (typically $>95\\%$) but not absolute. Crucially, its positivity is highly dependent on ongoing gluten consumption; levels decline on a gluten-free diet. The duodenal biopsy is the diagnostic gold standard and can indeed outweigh serological findings, especially in cases of seronegative celiac disease or when patients are already on a gluten-free diet.\n**Verdict: Incorrect**\n\n**C. HLA-DQ2 positivity alone is diagnostic of celiac disease; therefore, any biopsy findings are incidental and not required for diagnosis.**\nThis is incorrect. HLA-DQ2 or -DQ8 indicates genetic susceptibility, which is present in a large portion of the general population (approx. $30-40\\%$). The vast majority of these individuals never develop celiac disease. Therefore, HLA positivity has a very low positive predictive value and is not diagnostic on its own. It is primarily used for its high negative predictive value (a negative result essentially rules out celiac disease).\n**Verdict: Incorrect**\n\n**D. Marsh $3$ lesions are nonspecific and can be entirely explained by lactose intolerance after gluten challenge, so celiac disease is unlikely.**\nThis is incorrect. While villous atrophy (a component of Marsh $3$ lesions) is not entirely specific to celiac disease, it is highly characteristic, and its induction by a gluten challenge in an HLA-DQ2 positive individual is strongly indicative of celiac disease. Furthermore, lactose intolerance is a condition of enzyme deficiency (lactase) that causes symptoms like diarrhea but does *not* cause the severe immunologically-mediated mucosal destruction seen in Marsh $3$ lesions. Secondary lactose intolerance can be a *consequence* of the villous atrophy from celiac disease, not the cause of it.\n**Verdict: Incorrect**\n\n**E. Only endomysial antibody (EMA) seroconversion can diagnose celiac disease; without EMA positivity, the diagnosis cannot be made even in the presence of Marsh $3$ changes following gluten challenge.**\nThis is incorrect. EMA targets the same antigen as tTG-IgA. While highly specific, it is not the sole diagnostic criterion. The diagnostic cornerstone, particularly in complex or seronegative cases, is the duodenal biopsy demonstrating characteristic gluten-dependent enteropathy. A diagnosis of celiac disease can be, and often is, made in the absence of positive EMA or tTG-IgA serology when other criteria (genetics, clinical response to diet, and histology) are met.\n**Verdict: Incorrect**", "answer": "$$\\boxed{A}$$", "id": "4337174"}, {"introduction": "Villous atrophy is a hallmark of celiac disease, but it is not exclusive to it. This final practice presents a complex clinical case where you must act as a master diagnostician, integrating a wide range of clinical, serological, genetic, and pathological data to differentiate celiac disease from one of its great mimics. This exercise in differential diagnosis is a crucial step in developing expert clinical reasoning and highlights the importance of specific findings, like noncaseating granulomas, in pointing toward an alternative diagnosis [@problem_id:4337184].", "problem": "A patient aged $28$ years presents with $9$ months of intermittent watery diarrhea, $6$ kg unintentional weight loss, abdominal cramping, and fatigue. Laboratory evaluation shows microcytic anemia with hemoglobin $10.8\\ \\mathrm{g/dL}$ and mean corpuscular volume $74\\ \\mathrm{fL}$. Iron studies are consistent with iron deficiency. Stool studies are negative for ova and parasites, fat quantification is mildly elevated, and C-reactive protein is modestly elevated. Celiac serology reveals tissue transglutaminase immunoglobulin A (tTG-IgA) negative and endomysial antibody (EMA) negative. Total serum immunoglobulin A is $200\\ \\mathrm{mg/dL}$ (reference range $70$–$400\\ \\mathrm{mg/dL}$). Human Leukocyte Antigen (HLA) typing shows absence of HLA-DQ2 and HLA-DQ8. Esophagogastroduodenoscopy demonstrates patchy erythema in the second portion of the duodenum; biopsies show villous blunting, crypt hyperplasia, increased chronic inflammatory cells in the lamina propria, and multiple discrete, noncaseating granulomas. Acid-fast bacilli staining and mycobacterial polymerase chain reaction on the biopsy are negative. The patient has no recent travel to tropical regions and no history of recurrent sinopulmonary infections.\n\nBased on core definitions of disease mechanisms and well-tested diagnostic principles in gastrointestinal pathology, which diagnosis is most likely?\n\nA. Celiac disease (gluten-sensitive enteropathy)\n\nB. Crohn disease involving the proximal small intestine\n\nC. Tropical sprue\n\nD. Common variable immunodeficiency\n\nE. Intestinal tuberculosis", "solution": "The problem statement is a clinical case vignette that requires a differential diagnosis based on the provided clinical, laboratory, and pathological findings.\n\n### Step 1: Extract Givens\n- **Patient Demographics & History**:\n  - Age: $28$ years\n  - Duration of symptoms: $9$ months\n  - Symptoms: Intermittent watery diarrhea, $6$ kg unintentional weight loss, abdominal cramping, fatigue\n  - Travel History: No recent travel to tropical regions\n  - Medical History: No history of recurrent sinopulmonary infections\n- **Laboratory Findings**:\n  - Complete Blood Count: Microcytic anemia with hemoglobin $10.8\\ \\mathrm{g/dL}$ and mean corpuscular volume (MCV) $74\\ \\mathrm{fL}$\n  - Iron Studies: Consistent with iron deficiency\n  - Inflammatory Marker: C-reactive protein (CRP) is modestly elevated\n- **Stool Studies**:\n  - Microbiology: Negative for ova and parasites\n  - Chemistry: Mildly elevated fat quantification (steatorrhea)\n- **Serology & Immunology**:\n  - Celiac Serology: Tissue transglutaminase immunoglobulin A (tTG-IgA) negative, endomysial antibody (EMA) negative\n  - Total Serum Immunoglobulin A (IgA): $200\\ \\mathrm{mg/dL}$ (within reference range $70$–$400\\ \\mathrm{mg/dL}$)\n- **Genetics**:\n  - Human Leukocyte Antigen (HLA) typing: Absence of HLA-DQ2 and HLA-DQ8\n- **Endoscopy & Pathology**:\n  - Procedure: Esophagogastroduodenoscopy (EGD)\n  - Gross Findings: Patchy erythema in the second portion of the duodenum\n  - Histopathology (Biopsy): Villous blunting, crypt hyperplasia, increased chronic inflammatory cells in the lamina propria\n  - Key Histopathologic Finding: Multiple discrete, noncaseating granulomas\n  - Special Stains/Tests on Biopsy: Acid-fast bacilli (AFB) staining negative, mycobacterial polymerase chain reaction (PCR) negative\n\n### Step 2: Validate Using Extracted Givens\n1.  **Scientifically Grounded**: The problem presents a coherent and medically plausible clinical case. All symptoms, lab values, and pathological descriptions are standard in the field of gastroenterology and pathology. The differential diagnosis for malabsorption with the given features is a classic and fundamentally sound medical problem.\n2.  **Well-Posed**: The problem provides a rich set of positive and negative findings that are sufficient to logically deduce the most probable diagnosis from the given options. The question asks for the \"most likely\" diagnosis, which is appropriate for a clinical reasoning task.\n3.  **Objective**: The information is presented factually, using established medical terminology and quantitative data, devoid of subjective or biased language.\n\nThe problem statement is internally consistent, scientifically valid, and well-posed. No flaws are identified.\n\n### Step 3: Verdict and Action\nThe problem is valid. The solution process will proceed.\n\n### Derivation of the Correct Diagnosis\nThe patient presents with a chronic malabsorptive syndrome affecting the proximal small bowel, as evidenced by watery diarrhea, weight loss, steatorrhea, and iron deficiency anemia (iron is primarily absorbed in the duodenum). The duodenal biopsy confirms mucosal injury with villous blunting, crypt hyperplasia, and chronic inflammation. This histological pattern is non-specific and indicates an enteropathy. The key to the differential diagnosis lies in integrating the more specific findings.\n\nThe most specific and crucial finding is the presence of **multiple discrete, noncaseating granulomas** on the duodenal biopsy. Noncaseating granulomas are a hallmark of certain inflammatory and infectious conditions. We must evaluate the presented options in light of this finding and the other exclusionary data.\n\n1.  **Evaluation of Celiac Disease**: Although villous atrophy is characteristic of celiac disease, the diagnosis is definitively ruled out. First, the specific serological markers, tTG-IgA and EMA, are negative. The total serum IgA is normal ($200\\ \\mathrm{mg/dL}$), confirming that the negative serology is not due to a selective IgA deficiency. Second, the genetic screening is negative for HLA-DQ2 and HLA-DQ8. The absence of both haplotypes has a negative predictive value of over $99\\%$, making celiac disease extremely unlikely. Third, granulomas are not a feature of celiac disease.\n\n2.  **Evaluation of Infectious Etiologies**:\n    - **Intestinal Tuberculosis**: This is a primary consideration in the differential diagnosis of intestinal granulomas. However, the granulomas in tuberculosis are classically caseating. More importantly, specific tests to identify *Mycobacterium tuberculosis*—the acid-fast bacilli (AFB) stain and mycobacterial PCR on the biopsy specimen—were both negative. This strongly argues against tuberculosis.\n    - **Other infections**: Stool studies were negative for ova and parasites.\n\n3.  **Evaluation of Other Malabsorptive Syndromes**:\n    - **Tropical Sprue**: This is a syndrome of chronic malabsorption acquired in endemic tropical areas. The problem explicitly states there is no recent travel history to such regions, effectively excluding this diagnosis. Moreover, granulomas are not a typical feature.\n    - **Common Variable Immunodeficiency (CVID)**: This is a primary immunodeficiency that can present with a celiac-like enteropathy and, in some cases, granulomatous disease. However, CVID is defined by hypogammaglobulinemia (low IgG, and often low IgA/IgM) and is clinically associated with recurrent sinopulmonary infections. This patient has a normal serum IgA level and no history of recurrent infections, making CVID highly improbable.\n\n4.  **Evaluation of Crohn Disease**: Crohn disease is a chronic, idiopathic inflammatory bowel disease. It is characterized by transmural inflammation that can affect any part of the gastrointestinal tract, from the mouth to the anus, often in a discontinuous or \"patchy\" manner. Duodenal involvement occurs in a subset of patients and can present with the malabsorptive symptoms seen here. The defining histopathological feature of Crohn disease, present in about $30$-$50\\%$ of cases, is the presence of noncaseating granulomas. The patient's presentation with malabsorption, elevated inflammatory markers (CRP), patchy duodenal inflammation, and, most critically, noncaseating granulomas on biopsy in the absence of evidence for tuberculosis or other causes, is a classic picture of Crohn disease involving the proximal small intestine.\n\n**Conclusion**: Crohn disease provides the most comprehensive and consistent explanation for the entire constellation of findings.\n\n### Option-by-Option Analysis\n\n**A. Celiac disease (gluten-sensitive enteropathy)**\nThe histological findings of villous blunting and crypt hyperplasia are compatible with celiac disease. However, this diagnosis is conclusively ruled out by the combination of negative tTG-IgA and EMA serology (with a normal total IgA) and the absence of the requisite HLA-DQ2 and HLA-DQ8 genetic markers. The presence of noncaseating granulomas is also inconsistent with celiac disease.\n**Verdict: Incorrect.**\n\n**B. Crohn disease involving the proximal small intestine**\nThis diagnosis aligns perfectly with all the data. The patient has a chronic inflammatory malabsorptive syndrome. The endoscopy shows patchy inflammation, consistent with the \"skip lesion\" nature of Crohn disease. The biopsy confirms a chronic enteropathy with the pathognomonic finding of noncaseating granulomas. The negative tests for tuberculosis exclude the main mimic of granulomatous enteritis. Therefore, this is the most likely diagnosis.\n**Verdict: Correct.**\n\n**C. Tropical sprue**\nThis diagnosis is clinically excluded by the patient's history, which notes an absence of recent travel to endemic tropical regions. Additionally, noncaseating granulomas are not a characteristic finding in tropical sprue.\n**Verdict: Incorrect.**\n\n**D. Common variable immunodeficiency**\nThis diagnosis is inconsistent with the laboratory and clinical findings. The patient's total serum IgA level is normal ($200\\ \\mathrm{mg/dL}$), and there is no history of recurrent sinopulmonary infections, which are key features of CVID.\n**Verdict: Incorrect.**\n\n**E. Intestinal tuberculosis**\nWhile intestinal tuberculosis can present with granulomatous inflammation, the granulomas are typically caseating. Most importantly, specific diagnostic tests for *Mycobacterium tuberculosis* on the biopsy material, including both acid-fast bacilli (AFB) staining and mycobacterial polymerase chain reaction (PCR), were negative. This makes intestinal tuberculosis extremely unlikely.\n**Verdict: Incorrect.**", "answer": "$$\\boxed{B}$$", "id": "4337184"}]}